Bio-Rad Labs (BIO) Tops Q1 EPS by $2.21

Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $5.21, $2.21 better than the analyst estimate of $3.00. Revenue for the quarter came in at $726.8 million versus the consensus estimate of $660.98 million.

2021 Financial Outlook

For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth of approximately 5.5 to 6.0 percent and an estimated non-GAAP operating margin of approximately 17.0 percent. Management will discuss this outlook in greater detail on the first-quarter 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• Pullback in chip stocks is a buying opportunity, Citi says
• Noodles & Company (NDLS) Tops Q2 EPS by 26c ; Offers Guidance